Showing results (81-90 of 104) with videos related to
Sort By:
Pageof 11
Pharmacology Research & Perspectives|March 30, 2016
Preclinical pharmacology and pharmacokinetics of CERC-301, a GluN2B-selective N-methyl-D-aspartate receptor antagonistRachel Garner, Shobha Gopalakrishnan, John A McCauley, et al.Bioorganic & Medicinal Chemistry Letters|January 30, 2002
Discovery of a nonpeptidic small molecule antagonist of the human platelet thrombin receptor (PAR-1)Philippe G Nantermet, James C Barrow, George F Lundell, et al.Bioorganic & Medicinal Chemistry Letters|August 4, 2009
Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonistsCharles J McIntyre, John A McCauley, Bohumil Bednar, et al.Bioorganic & Medicinal Chemistry Letters|October 25, 2008
Potent benzimidazolone-based CGRP receptor antagonistsCory R Theberge, Rodney A Bednar, Ian M Bell, et al.Bioorganic & Medicinal Chemistry Letters|May 15, 2007
Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonistsKevin T Nguyen, Christopher F Claiborne, John A McCauley, et al.Bioorganic & Medicinal Chemistry Letters|October 10, 2001
Discovery and initial structure-activity relationships of trisubstituted ureas as thrombin receptor (PAR-1) antagonistsJ C Barrow, P G Nantermet, H G Selnick, et al.Journal of Medicinal Chemistry|July 8, 1999
Non-peptide GPIIb/IIIa inhibitors. 20. Centrally constrained thienothiophene alpha-sulfonamides are potent, long acting in vivo inhibitors of platelet aggregationM S Egbertson, J J Cook, B Bednar, et al.Bioorganic & Medicinal Chemistry Letters|August 26, 2009
Novel CGRP receptor antagonists through a design strategy of target simplification with addition of molecular flexibilityMichael R Wood, Kathy M Schirripa, June J Kim, et al.Bioorganic & Medicinal Chemistry Letters|January 22, 2008
Proline bis-amides as potent dual orexin receptor antagonistsJeffrey M Bergman, Anthony J Roecker, Swati P Mercer, et al.Bioorganic & Medicinal Chemistry Letters|November 13, 2013
Discovery of 2,5-diarylnicotinamides as selective orexin-2 receptor antagonists (2-SORAs)Swati P Mercer, Anthony J Roecker, Susan Garson, et al.Pageof 11